Effects of Remimazolam on Quality of Recovery After Ambulatory Surgery

Effects of Remimazolam Combined With Remifentanil on Quality of Recovery After Ambulatory Hysteroscopic Surgery: a Prospective, Observational Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05320016

Enrollment

Registered

2022-04-11

Start date

2021-11-01

Completion date

2021-12-31

Last updated

2022-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Day Surgery, Patient Outcome Assessment, Quality of Recovery, Remimazolam

Brief summary

Remimazolam is a novel ultra-short acting benzodiazepine with rapid onset of effects, short maintenance and faster recovery time. Due to its recent development, few studies have investigated the effect of remimazolam on postoperative recovery mainly focusing on physiologic endpoints, recovery time and possible adverse events. Although these parameters are crucial and need evaluation, the investigators ignore quality of recovery from participant's perspective. For this purpose, various measurment tools have been developed for psychometric evaluation of QoR score.

Detailed description

To date, there has not been a study investigating the impact of remimazolam on quality of recovery (QoR). This study evaluates the effect of remimazolam on QoR of participants undergoing general anesthesia using remimazolam-remifentanil total intravenous anesthesia (TIVA) for hysteroscopy as day surgery basis. Herein, the investigators used the translated Korean version of the 15-item Quality of Recovery-15 (QoR-15K) questionnaire, which was previously validated in Korean surgical participants.

Interventions

DRUGRemimazolam

Effects of remimazolam on quality of recovery scores after ambulatory hysteroscopic surgery

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

19 Years to 75 Years

Inclusion criteria

* Adult woman scheduled for ambulatory gynecological surgery under general anesthesia * American Society of Anesthesiology grade 1 or 2

Exclusion criteria

* Underlying diseases: liver, kidney, brain nervous system, glaucoma * Patients with BMI greater than 30 and less than 18.5 * Patients diagnosed with sleep apnea * Alcohol or drug dependent patients * Patients with severe or acute respiratory failure * Lactose intolerance * Dextran 40 hypersensitivity * Patients in shock or coma

Design outcomes

Primary

Measure	Time frame	Description
Quality of recovery	24 hours after ambulatory hysteroscopic surgery	the translated Korean version of 15-item Quality of Recovery scale (QoR-15K)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026